Tumors with p53 mutation are less dependent on vascular supply and are more resistant to antiangiogenic drug treatment.1135 Therefore, an in-depth investigation into the mechanisms of antiangiogenic drug resistance and tumor heterogeneity is a promising strategy for tumor treatment. The gene discussed is TP53; the disease is neoplasm.